COVID Research: No significant support from ivermectin, other drugs

A new study has found that three drugs, including the anti-parasitic ivermectin, have no significant effect on treating low oxygen levels or preventing ER visits, hospitalizations or deaths from COVID-19.

The study, published Thursday in the New England Journal of Medicine, compared the effectiveness of the type 2 diabetes drug metformin, low-dose fluvoxamine, an antidepressant, and ivermectin as a possible treatment. COVID-19 and long-term symptoms.

“None of the three drugs evaluated prevented the occurrence of hypoxemia, emergency department visits, hospitalization, or COVID-19-related death,” the study said. .

Although the researchers say metformin may offer possible benefits in preventing ER visits, hospitalizations, and death, the results are uncertain without other studies.

Of all the three drugs analyzed, ivermectin has received the most attention during the COVID-19 pandemic as a possible treatment for the disease.

Although the drug has proven to be an effective anti-parasitic drug, with its discoverers winning a Nobel Prize in 2015, results are still mixed on whether it can treat COVID. -19 or not.

Some studies have found ivermectin to be effective in a laboratory setting, but the researchers behind the latest New England Journal of Medicine study point out that some studies have linked ivermectin levels 50 to 100 times the levels achievable in humans.

After it was reported that some people were using the veterinary version of ivermectin, Health Canada issued advice in August 2021 asking people not to use the animal or human version of the drug. .

A total of 1,323 adults, all of whom were overweight or obese, participated in the recent study.

Participants received two drugs for three or 14 days, depending on the drug.

The pills are randomly assigned to patients in one of six ways: metformin plus fluvoxamine; metformin plus ivermectin; metformin plus placebo; fluvoxamine and placebo; ivermectin and placebo; or two placebos.

The mean age of the patients was 46 and 56% were female, of which 6.1% were pregnant.

Volunteers must register within three days of receiving a positive COVID-19 test and develop symptoms within seven days of being randomized to drug treatment. Fifty-two percent of the participants were vaccinated.

The study was limited because it included only overweight or obese patients, and only a small number of them were black or Latinx, the researchers said.

Source link


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button